Publications

Prediction of serotypes causing invasive pneumococcal disease in unvaccinated and vaccinated populations.

Weinberger, DM; Harboe, ZB; FLASCHE, S; SCOTT, JA; Lipsitch, M;

2011

Epidemiology (Cambridge, Mass), (2011).22 2 10.1097/EDE.0b013e3182087634.

Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.

ASANTE, KP; Abdulla, S; Agnandji, S; Lyimo, J; Vekemans, J; Soulanoudjingar, S; Owusu, R; Shomari, M; Leach, A; Jongert, E; Salim, N; Fernandes, JF; DOSOO, D; Chikawe, M; Issifou, S; Osei-Kwakye, K; Lievens, M; Paricek, M; Möller, T; Apanga, S; Mwangoka, G; Dubois, M-C; Madi, T; Kwara, E; Minja, R; ... Lell, B.

2011

The Lancet infectious diseases, (2011).11 10 10.1016/S1473-3099(11)70100-1.

Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine.

Swysen, C; Vekemans, J; Bruls, M; Oyakhirome, S; DRAKELEY, C; Kremsner, P; GREENWOOD, B; Ofori-Anyinam, O; Okech, B; Villafana, T; Carter, T; Savarese, B; Duse, A; Reijman, A; Ingram, C; Frean, J; Ogutu, B; Clinical Trials Partnership Committee,;

2011

Malaria journal, (2011).10 1 10.1186/1475-2875-10-223.

Age-specific incidence of A/H1N1 2009 influenza infection in England from sequential antibody prevalence data using likelihood-based estimation.

BAGUELIN, M; Hoschler, K; Stanford, E; Waight, P; Hardelid, P; Andrews, N; MILLER, E;

2011

PloS one, (2011).6 2 10.1371/journal.pone.0017074.

How does the level of BCG vaccine protection against tuberculosis fall over time?.

RODRIGUES, LC; MANGTANI, P; ABUBAKAR, I;

2011

BMJ (Clinical research ed), (2011).343 sep29 10.1136/bmj.d5974.

Post Marketing Vaccine Safety Monitoring in Low and Lower-Middle-Income Countries (LIC/LMIC).

Li, Y; Weibel, D; Eskola, J; LARSON, H; Zuber, P; Bonhoeffer, J;

2011

Pharmacoepidemiology and drug safety, (2011).20,

Social contact patterns in Vietnam and implications for the control of infectious diseases.

Horby, P; Pham, QT; Hens, N; Nguyen, TT Y; Le, QM; Dang, DT; Nguyen, ML; Nguyen, TH; ALEXANDER, N; EDMUNDS, WJ; Tran, ND; Fox, A; Nguyen, TH;

2011

PloS one, (2011).6 2 10.1371/journal.pone.0016965.

Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model.

JIT, M; Chapman, R; Hughes, O; Choi, YH;

2011

BMJ (Clinical research ed), (2011).343 sep27 10.1136/bmj.d5775.

Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors.

Bonsignori, M; Hwang, K-K; Chen, X; Tsao, C-Y; Morris, L; Gray, E; Marshall, DJ; Crump, JA; KAPIGA, SH; Sam, NE; Sinangil, F; Pancera, M; Yongping, Y; Zhang, B; Zhu, J; Kwong, PD; O'Dell, S; Mascola, JR; Wu, L; Nabel, GJ; Phogat, S; Seaman, MS; Whitesides, JF; Moody, MA; Kelsoe, G; ... Haynes, BF.

2011

Journal of virology, (2011).85 19 10.1128/JVI.05045-11.

Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial.

Olotu, A; Lusingu, J; Leach, A; Lievens, M; Vekemans, J; Msham, S; Lang, T; Gould, J; Dubois, M-C; Jongert, E; Vansadia, P; Carter, T; Njuguna, P; Awuondo, KO; Malabeja, A; Abdul, O; Gesase, S; Mturi, N; DRAKELEY, CJ; Savarese, B; Villafana, T; Lapierre, D; Ballou, WR; Cohen, J; Lemnge, MM; ... Bejon, P.

2011

The Lancet infectious diseases, (2011).11 2 10.1016/S1473-3099(10)70262-0.